Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Julia Chisholm; Henry Mandeville; Madeleine Adams; Veronique Minard-Collin; Timothy Rogers; Anna Kelsey; Janet Shipley; Rick R. van Rijn; Isabelle de Vries; Roelof van Ewijk; Bart de Keizer; Susanne A. Gatz; Michela Casanova; Lisa Lyngsie Hjalgrim; Charlotte Firth; Keith Wheatley; Pamela Kearns; Wenyu Liu; Amanda Kirkham; Helen Rees; Gianni Bisogno; Ajla Wasti; Sara Wakeling; Delphine Heenen; Deborah A. Tweddle; Johannes H.M. Merks; Meriel Jenney

doi:10.3390/cancers16050998

Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Julia Chisholm^*, Henry Mandeville, Madeleine Adams, Veronique Minard-Collin, Timothy Rogers, Anna Kelsey, Janet Shipley, Rick R. van Rijn, Isabelle de Vries, Roelof van Ewijk, Bart de Keizer, Susanne A. Gatz, Michela Casanova, Lisa Lyngsie Hjalgrim, Charlotte Firth, Keith Wheatley, Pamela Kearns, Wenyu Liu, Amanda Kirkham, Helen ReesGianni Bisogno, Ajla Wasti, Sara Wakeling, Delphine Heenen, Deborah A. Tweddle, Johannes H.M. Merks, Meriel Jenney

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [¹⁸F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.

Original language	English
Article number	998
Journal	Cancers
Volume	16
Issue number	5
DOIs	https://doi.org/10.3390/cancers16050998
Publication status	Published - Mar 2024
Externally published	Yes

Keywords

chemotherapy
clinical trial
EpSSG
FaR-RMS
novel agents
radiotherapy
randomisation
rhabdomyosarcoma

Access to Document

10.3390/cancers16050998

Cite this

Chisholm, J., Mandeville, H., Adams, M., Minard-Collin, V., Rogers, T., Kelsey, A., Shipley, J., van Rijn, R. R., de Vries, I., van Ewijk, R., de Keizer, B., Gatz, S. A., Casanova, M., Hjalgrim, L. L., Firth, C., Wheatley, K., Kearns, P., Liu, W., Kirkham, A., ... Jenney, M. (2024). Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers, 16(5), Article 998. https://doi.org/10.3390/cancers16050998

@article{2ea19f5036134396ad0902af3ec7e569,

title = "Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)",

abstract = "The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.",

keywords = "chemotherapy, clinical trial, EpSSG, FaR-RMS, novel agents, radiotherapy, randomisation, rhabdomyosarcoma",

author = "Julia Chisholm and Henry Mandeville and Madeleine Adams and Veronique Minard-Collin and Timothy Rogers and Anna Kelsey and Janet Shipley and {van Rijn}, {Rick R.} and {de Vries}, Isabelle and {van Ewijk}, Roelof and {de Keizer}, Bart and Gatz, {Susanne A.} and Michela Casanova and Hjalgrim, {Lisa Lyngsie} and Charlotte Firth and Keith Wheatley and Pamela Kearns and Wenyu Liu and Amanda Kirkham and Helen Rees and Gianni Bisogno and Ajla Wasti and Sara Wakeling and Delphine Heenen and Tweddle, {Deborah A.} and Merks, {Johannes H.M.} and Meriel Jenney",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = mar,

doi = "10.3390/cancers16050998",

language = "English",

volume = "16",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

Chisholm, J, Mandeville, H, Adams, M, Minard-Collin, V, Rogers, T, Kelsey, A, Shipley, J, van Rijn, RR, de Vries, I, van Ewijk, R, de Keizer, B, Gatz, SA, Casanova, M, Hjalgrim, LL, Firth, C, Wheatley, K, Kearns, P, Liu, W, Kirkham, A, Rees, H, Bisogno, G, Wasti, A, Wakeling, S, Heenen, D, Tweddle, DA, Merks, JHM & Jenney, M 2024, 'Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)', Cancers, vol. 16, no. 5, 998. https://doi.org/10.3390/cancers16050998

TY - JOUR

T1 - Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial

T2 - A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

AU - Chisholm, Julia

AU - Mandeville, Henry

AU - Adams, Madeleine

AU - Minard-Collin, Veronique

AU - Rogers, Timothy

AU - Kelsey, Anna

AU - Shipley, Janet

AU - van Rijn, Rick R.

AU - de Vries, Isabelle

AU - van Ewijk, Roelof

AU - de Keizer, Bart

AU - Gatz, Susanne A.

AU - Casanova, Michela

AU - Hjalgrim, Lisa Lyngsie

AU - Firth, Charlotte

AU - Wheatley, Keith

AU - Kearns, Pamela

AU - Liu, Wenyu

AU - Kirkham, Amanda

AU - Rees, Helen

AU - Bisogno, Gianni

AU - Wasti, Ajla

AU - Wakeling, Sara

AU - Heenen, Delphine

AU - Tweddle, Deborah A.

AU - Merks, Johannes H.M.

AU - Jenney, Meriel

PY - 2024/3

Y1 - 2024/3

N2 - The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.

AB - The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.

KW - chemotherapy

KW - clinical trial

KW - EpSSG

KW - FaR-RMS

KW - novel agents

KW - radiotherapy

KW - randomisation

KW - rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85187913556&partnerID=8YFLogxK

U2 - 10.3390/cancers16050998

DO - 10.3390/cancers16050998

M3 - Article

AN - SCOPUS:85187913556

SN - 2072-6694

VL - 16

JO - Cancers

JF - Cancers

IS - 5

M1 - 998

ER -

Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this